The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

Artificial intelligence chatbots cannot be relied on to give accurate, safe or even clear advice about medication, according ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...

Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

First you’ll need to log back into 23andMe, if you can remember your details that is. Then you can submit the deletion ...

GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

Locally advanced cervical cancer remains a substantial source of mortality, particularly in low-resource settings.1 ...

Commenting on the macroeconomic reality and its impact on the industrial sector, the Chartered Institute of Directors (CIoD) ...